RayKnowChina Research Map
Shortlist

JinanShandong University

Second Hospital of Shandong University

山东大学第二医院

Listed for 13 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Hospital of Shandong University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌10 papers led1 open trial led
  2. Hepatocellular carcinoma肝细胞癌41 papers led
  3. Stomach cancer胃癌22 papers led1 open trial led
  4. Osteosarcoma骨肉瘤15 papers led
  5. Neuroblastoma神经母细胞瘤1 paper led
  6. Multiple myeloma多发性骨髓瘤7 papers led
  7. Aplastic anaemia再生障碍性贫血2 papers led
  8. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  9. Myasthenia gravis重症肌无力2 papers led
  10. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  11. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  12. IgA nephropathyIgA 肾病1 paper led
  13. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 10 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
10
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 4420232024: 2220242025: 112025

6 hospitals in Jinan for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT07430579

    Age 18 years to 80 years (registered criteria)

    Led by Second Hospital of Shandong University; 1 listed hospital as study siteJinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsNeoadjuvant & combined treatment

Over half of these papers are lab or animal studies.

Papers it led10
  1. Disulfiram impairs USP21-mediated MOF-K257 deubiquitination to inhibit esophageal squamous cell carcinoma progression.2025Cancer letters
  2. miR-493-5p Silenced by DNA Methylation Promotes Angiogenesis via Exosomes and VEGF-A-Mediated Intracellular Cross-Talk Between ESCC Cells and HUVECs.2024International journal of nanomedicineFree full text
  3. Stabilization of MOF (KAT8) by USP10 promotes esophageal squamous cell carcinoma proliferation and metastasis through epigenetic activation of ANXA2/Wnt signaling.2024Oncogene
  4. The Function of lncRNA LINC00997 as a Diagnostic Marker in the Progression of Esophageal Squamous Cell Carcinoma.2023Annals of clinical and laboratory science
  5. Circular RNA circ-FIRRE interacts with HNRNPC to promote esophageal squamous cell carcinoma progression by stabilizing GLI2 mRNA.2023Cancer scienceFree full text
  6. CircABCA13 acts as a miR-4429 sponge to facilitate esophageal squamous cell carcinoma development by stabilizing SRXN1.2023Cancer scienceFree full text
  7. Exosomal miR-10527-5p Inhibits Migration, Invasion, Lymphangiogenesis and Lymphatic Metastasis by Affecting Wnt/β-Catenin Signaling via Rab10 in Esophageal Squamous Cell Carcinoma.2023International journal of nanomedicineFree full text
  8. USP36 facilitates esophageal squamous carcinoma progression via stabilizing YAP.2022Cell death & diseaseFree full text
  9. Construction and Evaluation of a Risk Score Model for Lymph Node Metastasis-Associated Circadian Clock Genes in Esophageal Squamous Carcinoma.2022CellsFree full text
  10. A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus.2021Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell CarcinomaRecruitingNCT07430579Lead sponsorN/AStart 2024-12
More papers found outside PubMed (not counted)3
  1. 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study2024Immuno-Oncology Technologyarticle
  2. Abstract 6847: IGF2BP3 promotes esophageal squamous cell carcinoma progressions via Wnt/CTNNB1 pathway2024Cancer Researchconference-abstract
  3. Construction of a survival model for Esophageal Squamous Carcinoma and prediction of potential treatment with herbal medicine2023Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 41 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
41
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 8820212022: 5520222023: 151520232024: 7720242025: 662025

6 hospitals in Jinan for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesHepatitis B & cirrhosisImmunotherapy & targeted drugsRecurrence & prognosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led41
  1. Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2025Academic radiology
  2. Nonlinear relationship between age and the risk of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.2025BMC infectious diseasesFree full text
  3. Identification of anoikis-related subtypes and a risk score prognosis model, the association with TME landscapes and therapeutic responses in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  4. Epigenetic modulation with nanosatellite triggers tumoricidal immunity for hepatocellular carcinoma treatment.2025Nature communicationsFree full text
  5. Ginsenoside Rb prevents the metastasis of hepatocarcinoma by blocking the platelet-tumor cell interaction.2025Naunyn-Schmiedeberg's archives of pharmacology
  6. Phthalate exposure and hepatocellular carcinoma: Unraveling mechanisms through network toxicology.2025Toxicology
  7. The double roles of T cell-mediated immune response in the progression of MASLD.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. The efficacy of sorafenib against hepatocellular carcinoma is enhanced by 5-aza-mediated inhibition of ID1 promoter methylation.2024FEBS open bioFree full text
  9. Attenuation of pro-tumorigenic senescent secretory phenotype by StN, a novel derivative of stevioside, potentiates its inhibitory activity on hepatocellular carcinoma.2024Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  10. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria.2024Hepatology communicationsFree full text
  11. HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells.2024Hepatology communicationsFree full text
  12. HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses T cell activity in hepatocellular carcinoma.2024Journal of translational medicineFree full text
  13. Elevated Hepatitis B virus RNA levels in hepatocellular carcinoma patients compared to cirrhotic individuals: A propensity score matched analysis.2024Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationFree full text
  14. Epirubicin may enhance the inhibition of hepatocellular carcinoma induced by iodine-125 seeds through downregulating WNT pathway.2023Asia-Pacific journal of clinical oncology
  15. IL-8-induced CXCR2 down-regulation in circulating monocytes in hepatocellular carcinoma is partially dependent on MAGL.2023BMC cancerFree full text
  16. From NAFLD to HCC: Advances in noninvasive diagnosis.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  17. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.2023Cancer immunology, immunotherapy : CIIFree full text
  18. MELK promotes HCC carcinogenesis through modulating cuproptosis-related gene DLAT-mediated mitochondrial function.2023Cell death & diseaseFree full text
  19. USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis.2023Cell death & diseaseFree full text
  20. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.2023Clinical and experimental medicine
  21. Bronchial artery chemoembolization with drug-eluting beads versus bronchial artery infusion followed by polyvinyl alcohol particles embolization for advanced squamous cell lung cancer: A retrospective study.2023European journal of radiology
  22. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.2023Expert review of gastroenterology & hepatology
  23. Decreased granzyme-B expression in CD11c+CD8+ T cells associated with disease progression in patients with HBV-related hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  24. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.2023Human & experimental toxicology
  25. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.2023International immunopharmacology
  26. The Association of Glycemic Index, Glycemic Load, and Daily Carbohydrates Intake with the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2023Nutrition and cancer
  27. Perfusion parameters of triphasic computed tomography hold preoperative prediction value for microvascular invasion in hepatocellular carcinoma.2023Scientific reportsFree full text
  28. Identification of Hub Genes and Immune Infiltration in Non-alcoholic Fatty Liver Disease -Related Hepatocellular Carcinoma by Bioinformatics Analysis.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  29. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer.2022Asia-Pacific journal of clinical oncologyFree full text
  30. Loss of WNK1 Suppressed the Malignant Behaviors of Hepatocellular Carcinoma Cells by Promoting Autophagy and Activating AMPK Pathway.2022Disease markersFree full text
  31. The causal relationship between white blood cell counts and hepatocellular carcinoma: a Mendelian randomization study.2022European journal of medical researchFree full text
  32. Involvement of NF-κB/PI3K/AKT signaling pathway in the protective effect of prunetin against a diethylnitrosamine induced hepatocellular carcinogenesis in rats.2022Journal of biochemical and molecular toxicology
  33. Identification and validation of the necroptosis-related gene signature related to prognosis and tumor immune in hepatocellular carcinoma.2022MedicineFree full text
  34. USP48 Is Upregulated by Mettl14 to Attenuate Hepatocellular Carcinoma via Regulating SIRT6 Stabilization.2021Cancer research
  35. HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.2021Cancer research
  36. lncRNA RBM5-AS1 promotes cell proliferation and invasion by epigenetically silencing miR-132/212 in hepatocellular carcinoma cells.2021Cell biology international
  37. Value of perfusion parameters and histogram analysis of triphasic computed tomography in pre-operative prediction of histological grade of hepatocellular carcinoma.2021Chinese medical journalFree full text
  38. Therapeutic efficacy of TACE 125I seed implantation and its combination with intra-tumor injection of cisplatin for the treatment of hepatocellular carcinoma.2021Indian journal of cancer
  39. Trans-jugular intrahepatic portosystemic shunt in patients with hepatic cellular carcinoma: A preliminary study.2021Journal of cancer research and therapeutics
  40. Higher Liver Stiffness Predicting Adverse Outcomes in Cirrhotic Patients with Child-Pugh Grades A and B.2021Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  41. Value of perfusion parameters histogram analysis of triphasic CT in differentiating intrahepatic mass forming cholangiocarcinoma from hepatocellular carcinoma.2021Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local AblationStatus unknownNCT03356236Study siteStart 2018-04
  2. Prospective Surveillance for Very Early Hepatocellular CarcinomaStatus unknownNCT03588442Study siteStart 2018-07
  3. Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma HugeStatus unknownNCT03277716Study siteN/AStart 2017-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 22 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
22
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 8820232024: 0020242025: 662025

7 hospitals in Jinan for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
    Phase
    N/A
    Started
    2020-07
    Registry
    NCT04688801

    Age 25 years to 80 years (registered criteria)

    Led by Second Hospital of Shandong UniversityJinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsImaging & AIPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicinePediatrics

Over half of these papers are lab or animal studies.

Papers it led22
  1. Nanoparticle-Mediated CXCL12-CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Machine learning-based integration develops a disulfidptosis-related lncRNA signature for improving outcomes in gastric cancer.2025Artificial cells, nanomedicine, and biotechnology
  3. Defining gastric cancer ecology: the crucial roles of TREM2+ macrophages and fibroblasts in tumor microenvironments.2025Communications biologyFree full text
  4. The regulatory role of integrin in gastric cancer tumor microenvironment and drug resistance.2025Progress in biophysics and molecular biology
  5. MicroRNA-32-5p promotes the proliferation and metastasis of gastric cancer cells.2025Scientific reportsFree full text
  6. Efficacy of quadratus lumborum block type 3 on postoperative cell-mediated immunity and analgesia for laparoscopic radical gastrectomy: a prospective randomized controlled trial.2025Surgical endoscopyRCT
  7. The Dual-Response-Single-Amplification Fluorescent Nanomachine for Tumor Imaging and Gastric Cancer Diagnosis.2023ACS nano
  8. DSC2 suppresses the growth of gastric cancer through the inhibition of nuclear translocation of γ-catenin and PTEN/PI3K/AKT signaling pathway.2023AgingFree full text
  9. Long Noncoding RNA Regulator of Reprogramming Regulates Cell Growth, Metastasis, and Cisplatin Resistance in Gastric Cancer via miR-519d-3p/HMGA2 Axis.2023Cancer biotherapy & radiopharmaceuticals
  10. GLIS3, a novel prognostic indicator of gastric adenocarcinoma, contributes to the malignant biological behaviors of tumor cells via modulating TGF-β1/TGFβR1/Smad1/5 signaling pathway.2023Cytokine
  11. Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  12. Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer.2023Journal of experimental & clinical cancer research : CRFree full text
  13. Gastric bacteria as potential biomarkers for the diagnosis of atrophic gastritis.2023Molecular biology reports
  14. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.2023Pathology, research and practice
  15. Identification of the ferroptosis-related ceRNA network related to prognosis and tumor immunity for gastric cancer.2022AgingFree full text
  16. Targeting kinesin family member 21B by miR-132-3p represses cell proliferation, migration and invasion in gastric cancer.2022BioengineeredFree full text
  17. Association of microRNA polymorphisms with gastric cancer risk in the North Chinese Han population.2022Journal of cancer research and therapeutics
  18. DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer.2022Journal of experimental & clinical cancer research : CRFree full text
  19. OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer.2022OncogeneFree full text
  20. Betulinic acid targets drug-resistant human gastric cancer cells by inducing autophagic cell death, suppresses cell migration and invasion, and modulates the ERK/MEK signaling pathway.2021Acta biochimica Polonica
  21. LncRNA DLEU2 is activated by STAT1 and induces gastric cancer development via targeting miR-23b-3p/NOTCH2 axis and Notch signaling pathway.2021Life sciences
  22. A recombinant adenovirus fiber knob protein sensitizes gastric cancer cells to trastuzumab.2021Panminerva medica
Chinese-language papers (not in the count)1
  1. [Clinicopathological features and research advances of fundic gland type neoplasms].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status4
  1. Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction CancerRecruitingNCT04688801Lead sponsorN/AStart 2020-07
  2. Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer TreatmentStatus unknownNCT04567069Lead sponsorPhase 1/Phase 2Start 2020-09
  3. Gut Microbiota and MetabonomicsStatus unknownNCT05205187Study siteStart 2022-02
  4. Multi-center and Multi-modal Deep Learning Study of Gastric CancerStatus unknownNCT05001321Study siteStart 2021-07

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 15 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 5520232024: 0020242025: 442025

18 hospitals in Jinan for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led15
  1. Vitamin B12 as a novel USP3 deubiquitinase inhibitor suppresses cell proliferation and growth in osteosarcoma.2025Biochemical and biophysical research communications
  2. Ziyuglycoside II suppressed the progression of osteosarcoma by coordinating estrogen-related receptor gamma and p53 signaling pathway.2025Chinese journal of natural medicines
  3. UBE2L3 Suppresses Oxidative Stress-regulated Necroptosis to Accelerate Osteosarcoma Progression.2025Recent patents on anti-cancer drug discovery
  4. Interfering with UBE2L3 expression targets regulation of MLKL to promote necroptosis inhibition of growth in osteosarcoma.2025World journal of surgical oncology
  5. Cytotoxic Effects of Castalin Nanoparticles Against Osteosarcoma.2023Applied biochemistry and biotechnology
  6. ADAM19 and TUBB1 Correlate with Tumor Infiltrating Immune Cells and Predicts Prognosis in Osteosarcoma.2023Combinatorial chemistry & high throughput screening
  7. Immune-based prognostic biomarkers associated with metastasis of osteosarcoma.2023General physiology and biophysics
  8. A-to-I RNA editing shows dramatic up-regulation in osteosarcoma and broadly regulates tumor-related genes by altering microRNA target regions.2023Journal of applied genetics
  9. New gene signature from the dominant infiltration immune cell type in osteosarcoma predicts overall survival.2023Scientific reports
  10. Intercalary frozen autografts for reconstruction of bone defects following meta-/diaphyseal tumor resection at the extremities.2022BMC musculoskeletal disorders
  11. Cost-Efficiency Optimization Serves as a Conserved Mechanism that Promotes Osteosarcoma in Mammals.2022Journal of molecular evolution
  12. An evolutionarily conserved mechanism that amplifies the effect of deleterious mutations in osteosarcoma.2022Molecular genetics and genomics : MGG
  13. Analysis of the function and mechanism of DIRAS1 in osteosarcoma.2022Tissue & cell
  14. CT45A1 promotes the metastasis of osteosarcoma cells in vitro and in vivo through β-catenin.2021Cell death & disease
  15. Bioinformatics integrated analysis to investigate candidate biomarkers and associated metabolites in osteosarcoma.2021Journal of orthopaedic surgery and research
Earlier papers (2016–2020)8
  1. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.2020Biochemical and biophysical research communications
  2. Long non-coding RNA TUSC7 suppresses osteosarcoma by targeting miR-211.2019Bioscience reports
  3. LncRNA LOC730101 promotes osteosarcoma cell survival under energy stress.2018Biochemical and biophysical research communications
  4. miRNA-20a upregulates TAK1 and increases proliferation in osteosarcoma cells.2018Future oncology (London, England)
  5. MiRNA-221 from tissue may predict the prognosis of patients with osteosarcoma.2018Medicine
  6. Expression and significance of calreticulin in human osteosarcoma.2017Cancer biomarkers : section A of Disease markers
  7. shRNA-mediated silencing of hTERT suppresses proliferation and promotes apoptosis in osteosarcoma cells.2017Cancer gene therapy
  8. High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma.2017Pathology, research and practice

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

8 hospitals in Jinan for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 7 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
7
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 2220242025: 112025

7 hospitals in Jinan for multiple myeloma175 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDrug combinationsDiagnosis, MRD & riskKidney & bone complications
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

6 hospitals in Jinan for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Papers it led2
  1. Annexin A1: a key regulator of T cell function and bone marrow adiposity in aplastic anaemia.2024The Journal of physiology
  2. Irisin protected hemopoietic stem cells and improved outcome of severe bone marrow failure.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic AnemiaStatus unknownNCT01182662Lead (inferred)Phase 2Start 2010-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

3 hospitals in Jinan for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisRelapse preventionImaging
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

4 hospitals in Jinan for myasthenia gravis89 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesThymus & thymectomyAntibodies & diagnosis
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

8 hospitals in Jinan for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Jinan for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Jinan for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Jinan for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Prognostic Value of Noninvasive Fibrosis Scores in Primary Biliary Cholangitis.2019Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

山东大学第二医院

Second Hospital of Shandong University

济南

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Qilu Hospital and The Second Hospital; Second Hospital of ShanDong University; Shandong University Second Hospital; SHSU

Suggest a correctionDownload the data